CTLA4 and neoplasm: One strategy to leverage the anti-tumor activity of CTLs involves activating pre-existing, endogenous tumor-directed CTL clones by administering immune checkpoint inhibitors or mAbs that block receptors such as PD-1 and CTLA-4 which are involved in T-cell-inhibitory pathways [16].